What the FDA labels say about taking them together
Carbamazepine and vilazodone
Vilazodone's FDA label of May 22, 2024 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name vilazodone. The vilazodone label: “Based on clinical response, consider increasing the dosage of VIIBRYD, over 1 to 2 weeks in patients taking strong CYP3A4 inducers for greater than 14 days.”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the vilazodone FDA label on DailyMed (effective May 22, 2024, Teva Pharmaceuticals, Inc.).
What does the carbamazepine label say about vilazodone?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name vilazodone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the vilazodone label say about carbamazepine?
Vilazodone label, drug interactionsConcomitant Drug Name or Drug Class: Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin); Clinical Rationale: The concomitant use of vilazodone hydrochloride and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of vilazodone hydrochloride alone [see Clinical Pharmacology ()].; Clinical Recommendation: Based on clinical response, consider increasing the dosage of vilazodone hydrochloride, over 1 to 2 weeks in patients taking strong CYP3A4 inducers for greater than 14 days [see Dosage and Administration (), Clinical Pharmacology ()].
Source: FDA drug label (Viibryd, NDA022567), Allergan, Inc., effective October 1, 2023 (SPL set 4c55ccfb-c4cf-11df-851a-0800200c9a66), via openFDA
Source: FDA drug label (Vilazodone Hydrochloride), Teva Pharmaceuticals, Inc., effective May 22, 2024 (SPL set 3a4745a0-de23-4b40-923e-0d7dfe6b8634), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Vilazodone | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $0.732 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once